Bal Pharma reports Q2 FY26 standalone and consolidated net loss of 6.41 lakhs
Bal Pharma published Q2 FY26 unaudited standalone and consolidated financial results, reporting a net loss of 6.41 lakhs for the quarter ended September 30, 2025, with EPS at (0.09).
The reported net loss directly impacts the company's profitability and can influence investor confidence, warranting a medium impact assessment.
The standalone and consolidated financial results for the quarter ended September 30, 2025, show a net loss of 6.41 lakhs, indicating a decline in profitability.
Bal Pharma Limited announced the newspaper publication of its unaudited standalone and consolidated financial results for the quarter ended September 30, 2025. * The results were approved by the Board of Directors on November 12, 2025. * They were subsequently published in Financial Express (English) and Sanjayvani (Kannada) on November 14, 2025. * For the quarter ended September 30, 2025, the company reported: * Standalone net loss of 6.41 lakhs, with total income from operations at 23.41 lakhs. * Consolidated net loss of 6.41 lakhs, with total income from operations at 23.41 lakhs. * Basic and Diluted Earnings Per Share (EPS) for both standalone and consolidated results stood at (0.09).
What to do with a filing like this
Bal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bal Pharma Limited. Read the original for the full detail.